Zoetis Inc (NYSE:ZTS) Shares Purchased by Zurich Insurance Group Ltd FI

Zurich Insurance Group Ltd FI increased its holdings in shares of Zoetis Inc (NYSE:ZTS) by 154.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 159,481 shares of the company’s stock after acquiring an additional 96,913 shares during the quarter. Zurich Insurance Group Ltd FI’s holdings in Zoetis were worth $18,099,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Glassman Wealth Services boosted its position in Zoetis by 306.5% during the first quarter. Glassman Wealth Services now owns 252 shares of the company’s stock worth $25,000 after acquiring an additional 190 shares during the last quarter. JJJ Advisors Inc. purchased a new position in Zoetis during the second quarter worth about $25,000. Altshuler Shaham Ltd raised its stake in Zoetis by 198.8% during the second quarter. Altshuler Shaham Ltd now owns 254 shares of the company’s stock worth $29,000 after purchasing an additional 169 shares during the period. Next Capital Management LLC raised its stake in Zoetis by 156.5% during the second quarter. Next Capital Management LLC now owns 295 shares of the company’s stock worth $33,000 after purchasing an additional 180 shares during the period. Finally, Destination Wealth Management raised its stake in Zoetis by 217.9% during the second quarter. Destination Wealth Management now owns 337 shares of the company’s stock worth $38,000 after purchasing an additional 231 shares during the period. Hedge funds and other institutional investors own 90.09% of the company’s stock.

In other news, EVP Kristin C. Peck sold 11,500 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $123.22, for a total value of $1,417,030.00. Following the completion of the transaction, the executive vice president now owns 48,877 shares in the company, valued at approximately $6,022,623.94. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Clinton A. Jr. Lewis sold 6,123 shares of the company’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $123.51, for a total transaction of $756,251.73. Following the completion of the transaction, the insider now owns 44,255 shares of the company’s stock, valued at approximately $5,465,935.05. The disclosure for this sale can be found here. Insiders sold 34,332 shares of company stock valued at $4,163,091 in the last 90 days. Company insiders own 0.29% of the company’s stock.

Shares of Zoetis stock traded up $0.83 on Friday, reaching $125.10. The company had a trading volume of 133,736 shares, compared to its average volume of 2,059,244. The firm’s 50 day moving average price is $123.64 and its two-hundred day moving average price is $109.75. The firm has a market cap of $59.97 billion, a PE ratio of 39.98, a PEG ratio of 3.09 and a beta of 0.87. Zoetis Inc has a 52-week low of $78.90 and a 52-week high of $130.08. The company has a debt-to-equity ratio of 2.74, a quick ratio of 2.87 and a current ratio of 4.17.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The business’s revenue was up 9.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.77 EPS. As a group, sell-side analysts predict that Zoetis Inc will post 3.57 EPS for the current year.

ZTS has been the topic of a number of analyst reports. Bank of America downgraded shares of Zoetis from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $111.00 to $120.00 in a research note on Monday, July 1st. They noted that the move was a valuation call. Barclays lifted their target price on shares of Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Argus set a $140.00 target price on shares of Zoetis and gave the stock a “buy” rating in a research note on Wednesday, September 4th. SunTrust Banks lifted their target price on shares of Zoetis from $120.00 to $130.00 and gave the stock a “hold” rating in a research note on Tuesday, August 13th. Finally, Craig Hallum lifted their target price on shares of Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Seven research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Zoetis currently has a consensus rating of “Buy” and a consensus price target of $120.94.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: How analysts view the yield curve

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit